AB-FUBINACA is a drug that acts as a potent agonist for the cannabinoid receptors, with Ki values of 0.9 nM at CB1 and 23.2 nM at CB2 and EC50 values of 1.8 nM at CB1 and 3.2 nM at CB2. It was originally developed by Pfizer in 2009 as an analgesic medication but was never pursued for human use. In 2012, it was discovered as an ingredient in synthetic cannabinoid blends in Japan, along with a related compound AB-PINACA, which had not previously been reported.
Synthetic cannabinoids are a class of molecules that bind to the same receptors to which cannabinoids in cannabis plants THC and CBD attach. They are designer drugs, commonly sprayed onto plant matter and are usually smoked, although they have also been ingested as a concentrated liquid form in the US and UK. They have been marketed as herbal incense, or “herbal smoking blends”, and sold under common names like K2, Spice, and Synthetic Marijuana. They are often labeled “not for human consumption” for liability defense. A large and complex variety of synthetic cannabinoids are designed in an attempt to avoid legal restrictions on cannabis, making synthetic cannabinoids designer drugs.
Remember, keep this and all other medicines out of the reach of children, never share your medicines with others, and use this drugs only for the indication prescribed.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.